Business profile & competitive position
Church & Dwight Co., Inc. operates in the Consumer Defensive sector under the Household & Personal Products industry classification. The company develops, manufactures, and markets a broad portfolio of consumer household and personal-care products, supplemented by specialty products serving animal nutrition, specialty chemicals, and commercial/professional cleaning end markets. Its recognized consumer brands include ARM & HAMMER, OXICLEAN, BATISTE, WATERPIK, THERABREATH, HERO, TOUCHLAND, TROJAN, FIRST RESPONSE, NAIR, ORAJEL, XTRA, and ZICAM. Operations are organized through three reportable segments: Consumer Domestic, Consumer International, and the Specialty Products Division.
The financial profile suggests a business with durable but mass-market economics. The reported net margin of 12.4% and return on equity of 18.2% reflect a company that converts brand equity into consistent profitability and generates above-cost-of-capital returns. A beta of 0.45 indicates low equity-market sensitivity, which is typical for a staples portfolio anchored by repeat-purchase household goods. At the same time, those metrics do not imply a wide-moat, premium-priced franchise comparable to high-margin beauty or spirits businesses; rather, they point to a scale-driven, cost-conscious operator competing on shelf presence, distribution reach, and household-brand recognition.
Two portfolio facts underscore that concentration. First, the seven designated "power brands" represented approximately 70% of consolidated net sales and profits in 2025, meaning growth hinges heavily on a relatively small set of trademarks. Second, Walmart accounted for about 23% of consolidated net sales in 2025, and no other customer exceeded 10% over the prior three years. Within the Consumer Domestic segment, household products represented roughly 54% of segment net sales and personal-care products represented roughly 46% in 2025. That mix makes CHD a balanced but U.S.-centric staples play with meaningful customer concentration.
Financial posture
Church & Dwight currently commands a $26.3 billion market capitalization and trades at a P/E ratio of 34.1. That multiple sits well above the long-run average for large-cap consumer staples and implies the market is pricing in above-average earnings growth, strong brand durability, or a reliable defensive cash-flow stream. The 12.4% net margin and 18.2% ROE support a quality-premium narrative, because both figures indicate the company deploys capital efficiently and retains pricing power relative to input costs.
The beta of 0.45 is equally informative from a portfolio-construction standpoint. CHD behaves more like a bond-proxy defensive holding than a cyclical consumer name; earnings volatility tends to be lower than the broader market, but the valuation multiple already captures that stability. For an investor, the combination of a mid-cap-to-large-cap defensive label, high-single-digit-to-low-double-digit profitability, and a 34x earnings multiple is the central tension: the business looks solid, but the market has already paid up for that solidity. Debt or leverage is not specified in the current data snapshot, so any assessment of balance-sheet risk should reference the company's filings rather than inferring a position.
Strategic priorities & outlook
According to the company's most recent SEC 10-K filing, Church & Dwight has four near-term operational priorities:
- Portfolio repositioning: Management is refocusing the mix toward faster-growing value and premium product lines after exiting the Flawless, Spinbrush, Waterpik showerhead, and VMS (vitamins, minerals, supplements) brands.
- Touchland integration: The company acquired Touchland hand sanitizer and is working to realize its intended contribution to sales and earnings.
- Global expansion of power brands: CHD intends to expand its seven power brands internationally, citing their potential for significant global growth.
- Supply-chain resilience: The company maintains qualified dual sources for roughly 70% of direct materials spend, a direct response to supply-chain volatility in recent years.
These priorities collectively signal a shift toward fewer, larger, faster-growing brands and a more geographically diversified revenue base, while the dual-sourcing target attempts to protect margins from supplier disruptions.
Macro & geopolitical exposure
As a Household & Personal Products company, Church & Dwight faces exposures common to the broader staples category rather than idiosyncratic geopolitical bets. The sector is generally recession-resistant because consumers continue buying laundry detergent, toothpaste, and personal-care basics, but it is not immune to macro forces.
Key exposures include commodity input costs (resins, paperboard, chemicals, and agricultural-derived materials), freight and logistics costs, and currency translation for the Consumer International segment. The concentrated retail environment means negotiations with Walmart and other mass merchants directly affect pricing and shelf space. Regulatory risk is also material: personal-care and over-the-healthcare-adjacent products such as oral care, pregnancy tests, and condoms are subject to FDA, FTC, and state-level labeling oversight. Tariffs on raw materials or imported finished goods can pressure margins, while private-label competition can constrain pricing power in slower-growth categories.
Recent developments
The most recent headline flow, captured on November 8 and 7, 2026, is mixed between unrelated biotech news and company-specific activity:
- [2026-11-08, gurufocus.com] Vir Biotechnology announced that its pivotal Phase 3 ECLIPSE 1 trial for Elebsiran and Tobevibart in chronic hepatitis delta met its primary endpoint.
- [2026-11-08, gurufocus.com] Vir Biotechnology also reported expanded Phase 2 SOLSTICE data for the same hepatitis-delta regimen, showing sustained viral suppression and exploratory finite-treatment results.
- [2026-11-07, seekingingalpha.com] "69 Dividend Champions Ranked By Quality Scores (November 2026)" included Church & Dwight in a dividend-quality screen.
- [2026-11-07, defenseworld.net] "Insider Selling: Church & Dwight (NYSE:CHD) CEO Sells $9,133,230.60 in Stock" reported a sizable CEO sale totaling just over $9.1 million.
The Vir Biotechnology headlines appear in CHD's news feed but relate to a different company and do not carry direct fundamental implications for Church & Dwight. The dividend-quality listing is consistent with CHD's defensive, cash-generative profile. The CEO sale, however, is company-specific and worth monitoring, though insider transactions can reflect personal liquidity planning as much as a directional view.
Earnings behavior & post-earnings drift
Church & Dwight has a strong recent earnings record. Over the last eight reported quarters, the company beat expectations 6 out of 8 times, or 75% (often rounded from the raw 6/8 count), with an average earnings surprise of 3.5%. The average 5-day price move following the report is +2.05%, with the post-earnings drift classified as "up."
The most recent four quarters illustrate that the drift can be stronger than the one-day reaction:
- 2026-10-30: Actual EPS $0.92 vs. estimate $0.90, a 2.2% positive surprise and a beat. The stock rose 3.00% the next day and 1.96% over the following five days.
- 2026-07-31: Actual EPS $0.89 vs. estimate $0.896, a -0.7% surprise and a miss. The stock still rose 1.21% the next day and 4.48% over the following five days.
- 2026-05-01: Actual EPS $0.95 vs. estimate $0.931, a 2.0% positive surprise and a beat. The stock fell -3.26% the next day and -2.69% over the following five days.
- 2026-01-30: Actual EPS $0.86 vs. estimate $0.836, a 2.9% positive surprise and a beat. The stock rose 1.13% the next day and 4.45% over the following five days.
This pattern highlights that CHD's post-earnings price action is not always aligned with the immediate headline beat or miss, and that the unofficial consensus can differ from the reported estimate in subtle ways. The next scheduled report is January 29, 2027, before the market open, with a consensus EPS estimate of $1.01. At the time of this snapshot, CHD is trading at $111.31, with an RSI of 66.4 and a 50-day EMA of $102.71.
For a deeper dive into how institutional analysts are positioning around the upcoming report, valuation debates, and forward estimate revisions, readers should review the full institutional verdict and consensus breakdown rather than relying on the headline figures alone.
Frequently Asked Questions
What does Church & Dwight actually sell?
Church & Dwight is a consumer staples company operating in Household & Personal Products. It markets brands such as ARM & HAMMER, OXICLEAN, BATISTE, WATERPIK, THERABREATH, TOUCHLAND, TROJAN, FIRST RESPONSE, NAIR, ORAJEL, XTRA, and ZICAM. It also sells specialty products for animal nutrition, specialty chemicals, and commercial/professional cleaners, organized into Consumer Domestic, Consumer International, and Specialty Products Division segments.
How has CHD performed around earnings recently?
Over the last eight reported quarters, Church & Dwight beat estimates 6 out of 8 times, with an average earnings surprise of 3.5%. The average 5-day post-earnings drift has been +2.05%, classified as "up." However, individual quarters can diverge: for example, the May 1, 2026 beat was followed by a -3.26% next-day decline and a -2.69% five-day drift.
What are Church & Dwight's current strategic priorities?
Per its latest 10-K, CHD is prioritizing repositioning the portfolio toward faster-growing value and premium lines after exiting Flawless, Spinbrush, Waterpik showerhead, and VMS brands; integrating the Touchland hand-sanitizer acquisition; expanding its seven power brands globally; and maintaining qualified dual sources for roughly 70% of direct materials spend to reinforce supply-chain resilience.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-10-30 | $0.92 | $0.9 | +2.2% | +3% | +1.96% |
| 2026-07-31 | $0.89 | $0.896 | -0.7% | +1.21% | +4.48% |
| 2026-05-01 | $0.95 | $0.931 | +2% | -3.26% | -2.69% |
| 2026-01-30 | $0.86 | $0.836 | +2.9% | +1.13% | +4.45% |
| 2025-10-31 | $0.81 | $0.736 | +10.1% | - | - |
| 2025-08-01 | $0.94 | $0.857 | +9.7% | - | - |
Previous CHD editions
Get the institutional verdict on CHD
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the CHD verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.